Literature DB >> 26327602

Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates.

Michael Bröker1.   

Abstract

When tetanus toxoid (TT), diphtheria toxoid (DT) or Cross Reacting Material 197 (CRM197), a non-toxic diphtheria toxin mutant protein, are used as carrier proteins in glycoconjugate vaccines, these carriers induce a protein specific antibody response as measured by in vitro assays. Here, it was evaluated whether or not glycoconjugates based on TT, DT or CRM197 can induce a protective immune response as measured by potency tests according to the European Pharmacopoeia. It could be shown, that the conjugate carriers TT and DT can induce a protective immune response against a lethal challenge by toxins in animals, while glycoconjugates based on CRM197 failed to induce a protective immune response. Opportunities for new applications of glycoconjugates are discussed.

Entities:  

Keywords:  Cross Reacting Material 197; carrier proteins; combination vaccines; diphtheria toxoid; glycoconjugates; protective immunity; tetanus toxoid

Mesh:

Substances:

Year:  2016        PMID: 26327602      PMCID: PMC4964734          DOI: 10.1080/21645515.2015.1086048

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  4 in total

Review 1.  Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications.

Authors:  Michael Bröker; Paolo Costantino; Lisa DeTora; E David McIntosh; Rino Rappuoli
Journal:  Biologicals       Date:  2011-06-28       Impact factor: 1.856

Review 2.  Evolving meningococcal immunization strategies.

Authors:  Marco Aurélio Sáfadi; Julie A Bettinger; Gabriela Moreno Maturana; Godwin Enwere; Ray Borrow
Journal:  Expert Rev Vaccines       Date:  2014-12-10       Impact factor: 5.217

Review 3.  Glycoconjugate vaccines: an update.

Authors:  Mairi Vella; David Pace
Journal:  Expert Opin Biol Ther       Date:  2014-12-11       Impact factor: 4.388

4.  Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines.

Authors:  Kay Lockyer; Fang Gao; Jeremy P Derrick; Barbara Bolgiano
Journal:  Vaccine       Date:  2015-01-29       Impact factor: 3.641

  4 in total
  6 in total

Review 1.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

Review 2.  Advances in immunotherapy for the treatment of glioblastoma.

Authors:  Amanda Tivnan; Tatjana Heilinger; Ed C Lavelle; Jochen H M Prehn
Journal:  J Neurooncol       Date:  2016-10-14       Impact factor: 4.130

Review 3.  A Vaccine Against Group B Streptococcus: Recent Advances.

Authors:  Clara Carreras-Abad; Laxmee Ramkhelawon; Paul T Heath; Kirsty Le Doare
Journal:  Infect Drug Resist       Date:  2020-04-29       Impact factor: 4.003

4.  A Mouse Immunogenicity Model for the Evaluation of Meningococcal Conjugate Vaccines.

Authors:  Arun B Arunachalam; Stacey Vile; Angel Rosas
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

Review 5.  Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

Authors:  Michael Bröker; Francesco Berti; Paolo Costantino
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

6.  A Porphyromonas gingivalis Capsule-Conjugate Vaccine Protects From Experimental Oral Bone Loss.

Authors:  Fernanda G Rocha; Aym Berges; Angie Sedra; Shirin Ghods; Neeraj Kapoor; Lucy Pill; Mary Ellen Davey; Jeff Fairman; Frank C Gibson
Journal:  Front Oral Health       Date:  2021-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.